Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039442 · ClinicalTrials.gov registry record · Phase 2
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00039442 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 21 participants.
The verdict
NCT00039442, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG Capecitabine
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2002-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039442
The ClinicalTrials.gov registry entry for NCT00039442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00039442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039442 about?
NCT00039442 is a clinical study titled "Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer". Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00039442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2002-04-29.
What interventions are being tested in trial NCT00039442?
The interventions under investigation include: Capecitabine (DRUG), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT00039442?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.